DiscoverProject Oncology®Insights from ICARUS-Lung01: Efficacy and Safety of Dato-DXd for NSCLC
Insights from ICARUS-Lung01: Efficacy and Safety of Dato-DXd for NSCLC

Insights from ICARUS-Lung01: Efficacy and Safety of Dato-DXd for NSCLC

Update: 2024-09-09
Share

Description

Host: Charles Turck, PharmD, BCPS, BCCCP


Guest: Joshua E. Reuss, MD




The phase 2 ICARUS-Lung01 study evaluated not only the efficacy and safety of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), but also potential biomarkers associated with response and/or resistance. Here to discuss the findings with Dr. Charles Turck is Dr. Joshua Reuss, Assistant Professor in the Department of Medicine at Georgetown University Medical Center.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Insights from ICARUS-Lung01: Efficacy and Safety of Dato-DXd for NSCLC

Insights from ICARUS-Lung01: Efficacy and Safety of Dato-DXd for NSCLC